Skye Bioscience (SKYE) Competitors

Skye Bioscience (NASDAQ:SKYE) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Which has more risk & volatility, SKYE or YMAB?

Skye Bioscience has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.

Does the media refer more to SKYE or YMAB?

In the previous week, Skye Bioscience had 9 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 10 mentions for Skye Bioscience and 1 mentions for Y-mAbs Therapeutics. Skye Bioscience's average media sentiment score of 0.75 beat Y-mAbs Therapeutics' score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Skye Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Y-mAbs Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders have more ownership in SKYE or YMAB?

21.1% of Skye Bioscience shares are owned by institutional investors. Comparatively, 70.9% of Y-mAbs Therapeutics shares are owned by institutional investors. 4.5% of Skye Bioscience shares are owned by company insiders. Comparatively, 19.7% of Y-mAbs Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Is SKYE or YMAB more profitable?

Skye Bioscience has a net margin of 0.00% compared to Y-mAbs Therapeutics' net margin of -26.03%. Y-mAbs Therapeutics' return on equity of -24.60% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-76.03%	-69.20%
Y-mAbs Therapeutics	-26.03%	-24.60%	-18.89%

Do analysts prefer SKYE or YMAB?

Skye Bioscience presently has a consensus target price of $15.50, suggesting a potential upside of 371.12%. Y-mAbs Therapeutics has a consensus target price of $9.62, suggesting a potential upside of 12.80%. Given Skye Bioscience's stronger consensus rating and higher probable upside, equities analysts plainly believe Skye Bioscience is more favorable than Y-mAbs Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Y-mAbs Therapeutics	2 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Which has better earnings & valuation, SKYE or YMAB?

Skye Bioscience has higher earnings, but lower revenue than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$26.57M	-$1.06	-3.10
Y-mAbs Therapeutics	$87.68M	4.42	-$29.67M	-$0.50	-17.06

Summary

Skye Bioscience beats Y-mAbs Therapeutics on 10 of the 16 factors compared between the two stocks.